ArticleJCI insight2019

Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program.

Stefanie Geisler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.